Protectiveness of NAM-based hazard assessment - which testing scope is required?

NAMs benchmark dose modelling qIVIVE systemic toxicity tiered hazard assessment

Journal

ALTEX
ISSN: 1868-8551
Titre abrégé: ALTEX
Pays: Germany
ID NLM: 100953980

Informations de publication

Date de publication:
04 Dec 2023
Historique:
received: 08 09 2023
accepted: 24 11 2023
medline: 4 12 2023
pubmed: 4 12 2023
entrez: 4 12 2023
Statut: aheadofprint

Résumé

Hazard assessment (HA) requires toxicity tests to allow deriving protective points of departure (PoDs) for risk assessment irrespective of a compound's mode of action (MoA). The scope of in vitro test batteries (ivTB) thereby necessitated for systemic toxicity is still unclear. We explored the protectiveness regarding systemic toxicity of an ivTB with a scope, which was guided by previous findings from rodent studies, where examining six main targets, including liver and kidney, was sufficient to predict the guideline scope-based PoD with high probability. The ivTB comprises human in vitro models representing liver, kidney, lung and the neuronal system covering transcriptome, mitochondrial dysfunction and neuronal outgrowth. Additionally, 32 CALUX®- and 10 HepG2 BAC-GFP reporters cover a broad range of disturbance mechanisms. Eight compounds were chosen for causing adverse effects such as immunotoxicity or anemia in vivo, i.e., effects not directly covered by assays in the ivTB. PoDs derived from the ivTB and from oral repeated dose studies in rodents were extrapolated to maximum unbound plasma concentrations for comparison. The ivTB-based PoDs were one to five orders of magnitude lower than in vivo PoDs for six of eight compounds, implying that they were protective. The extent of in vitro response varied across test compounds. Especially for hematotoxic substances, the ivTB showed either no response or only cytotoxicity. Assays better capturing this type of hazard would be needed to complement the ivTB. This study highlights the potentially broad applicability of ivTBs for deriving protective PoDs of compounds with unknown MoA. Animal tests are used to determine which amount of a chemical is toxic (‘threshold of toxicity’) and which organs are affected. In principle, the threshold can also be derived solely from tests with cultured cells. However, only a limited number of cell types can practically be tested, so one challenge is to determine how many and which types shall be tested. In animal studies, only few organs including liver and kidney are regularly among those most sensitively affected. We explored whether a cell-based test battery representing these sensitive organs and covering important mechanisms of toxicity can be used to derive protective human thresholds. To challenge this approach, eight chemicals were tested that primarily cause effects in organs not directly represented in our test battery. Results provided protective thresholds for most of the investigated compounds and gave indications how to further improve the approach towards a full-fledged replacement for animal tests.

Autres résumés

Type: plain-language-summary (eng)
Animal tests are used to determine which amount of a chemical is toxic (‘threshold of toxicity’) and which organs are affected. In principle, the threshold can also be derived solely from tests with cultured cells. However, only a limited number of cell types can practically be tested, so one challenge is to determine how many and which types shall be tested. In animal studies, only few organs including liver and kidney are regularly among those most sensitively affected. We explored whether a cell-based test battery representing these sensitive organs and covering important mechanisms of toxicity can be used to derive protective human thresholds. To challenge this approach, eight chemicals were tested that primarily cause effects in organs not directly represented in our test battery. Results provided protective thresholds for most of the investigated compounds and gave indications how to further improve the approach towards a full-fledged replacement for animal tests.

Identifiants

pubmed: 38048429
doi: 10.14573/altex.2309081
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Auteurs

Walter Zobl (W)

Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.

Annette Bitsch (A)

Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.

Jonathan Blum (J)

University of Konstanz, Konstanz, Germany.

Jan J W A Boei (JJWA)

Leiden University Medical Center, Leiden, The Netherlands.

Liliana Capinha (L)

Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Giada Carta (G)

Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Jose Castell (J)

Instituto de Investigación Sanitaria La Fe, CIBEREHD, CIBERBBN, Valencia, Spain.

Enrico Davoli (E)

Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Milan, Italy.

Christina Drake (C)

Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.

Ciaran P Fisher (CP)

Certara - Simcyp Division, Sheffield, United Kingdom.

Muriel M Heldring (MM)

Leiden University, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.

Barira Islam (B)

Certara - Simcyp Division, Sheffield, United Kingdom.

Paul Jennings (P)

Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.

Marcel Leist (M)

University of Konstanz, Konstanz, Germany.

Damiano Pellegrino-Coppola (D)

Leiden University, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.

Johannes P Schimming (JP)

Leiden University, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.

Kirsten E Snijders (KE)

Leiden University, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.

Laia Tolosa (L)

Instituto de Investigación Sanitaria La Fe, CIBEREHD, CIBERBBN, Valencia, Spain.

Bob van de Water (B)

Leiden University, Leiden Academic Centre for Drug Research, Leiden, The Netherlands.

Barbara M A van Vugt-Lussenburg (BMA)

BioDetection Systems, Amsterdam, The Netherlands.

Paul Walker (P)

Cyprotex Discovery Ltd UK, Macclesfield, United Kingdom.

Matthias M Wehr (MM)

Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany.

Classifications MeSH